Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014.
Henry B, Revest M, Dournon N, Epelboin L, Mellon G, Bellaud G, Mordant P, Le Dû D, Véziris N, Bernard C, Morel S, Jauréguiberry S, Michelet C, Bricaire F, Tattevin P, Caumes É. Henry B, et al. Among authors: caumes e. Emerg Infect Dis. 2016 Mar;22(3):518-21. doi: 10.3201/eid2203.151130. Emerg Infect Dis. 2016. PMID: 26891089 Free PMC article.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, Fréchet-Jachym M; French MDR-TB Management Group. Guglielmetti L, et al. Among authors: caumes e. Eur Respir J. 2017 Mar 22;49(3):1601799. doi: 10.1183/13993003.01799-2016. Print 2017 Mar. Eur Respir J. 2017. PMID: 28182570 Free article.
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C. Mbuagbaw L, et al. Among authors: caumes e. Emerg Infect Dis. 2019 May;25(5):936-943. doi: 10.3201/eid2505.181823. Emerg Infect Dis. 2019. PMID: 31002070 Free PMC article.
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Guglielmetti L, et al. Among authors: caumes e. Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15. Clin Infect Dis. 2015. PMID: 25320286
Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment.
Eimer J, Fréchet-Jachym M, Le Dû D, Caumes E, El-Helali N, Marigot-Outtandy D, Mechai F, Peytavin G, Pourcher V, Rioux C, Yazdanpanah Y, Robert J, Guglielmetti L; LZDM group. Eimer J, et al. Among authors: caumes e. Clin Infect Dis. 2023 Feb 8;76(3):e947-e956. doi: 10.1093/cid/ciac485. Clin Infect Dis. 2023. PMID: 35717636
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, Yazdanpanah Y, Kuksa L, Caumes E, Fréchet-Jachym M. Guglielmetti L, et al. Among authors: caumes e. Eur Respir J. 2018 Mar 22;51(3):1702550. doi: 10.1183/13993003.02550-2017. Print 2018 Mar. Eur Respir J. 2018. PMID: 29419439 Free article. No abstract available.
511 results